March #162 : Shifting the Starting Lines - by Laura Whitehorn

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
E-newsletters
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join
Username:
Password:

Back to home » Archives » POZ Magazine issues




Table of Contents
 

Leading Ladies

Wonder Women




Crystal Clear

Go With the Flow

A Tell-Tale Heart

Going Rogue

Medicine Chest

Shifting the Starting Lines

The Power of Pampering




POZ Q&A: Senator Kirsten Gillibrand

Big Talk in the Big Apple

Faith in Numbers

Tropic Thunder

Are You Positive You’re Negative?




Editor's Letter-March 2010

Your Feedback-March 2010

In Memoriam

GMHC Treatment Issues-March 2010



 
Most Popular Lessons

The HIV Life Cycle

Shingles

Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV


Scroll down to comment on this story.


email print

March 2010


Shifting the Starting Lines

by Laura Whitehorn

Late last year, U.S., European and global HIV treatment guidelines all included new recommendations for when to start HIV meds. The trend is to begin earlier, but specifics vary—and questions remain. Below, a recap.

Stateside
U.S. guidelines, which previously suggested starting HIV treatment when CD4 counts fell below 350, have been revised to encourage people to begin when their CD4 counts are as high as 500. But guidelines committee members (researchers, clinicians and community activists) disagreed on whether to make the new recommendation “strong” or “moderate.”

Committee member Heidi Nass of the University of Wisconsin’s HIV/AIDS program in Madison told POZ, “If evidence fully established the benefit of starting [at CD4 counts as high as 500], we’d be looking at an A-1 rating. Instead, some feel this change is too much, too fast, with too little [evidence], while others feel that the data [already] justify putting the early start option on the table, to be sorted through between an individual and a doctor. As my own HIV doctor likes to say, ‘They’re just guidelines.’”
aidsinfo.nih.gov
P.O. Box 6303, Rockville, MD 20849-6303

In Europe
While the European AIDS Clinical Society (EACS) still recommends starting meds at 350 CD4 cells or below, the guidelines now add that people who also have hepatitis, HIV-associated kidney disease or another organ illness should begin treatment when CD4s are as high as 500. The EACS guidelines also detail special HIV-treatment advice for people with heart disease and other medical conditions.
Europeanaidsclinicalsociety.org/guidelines.asp

In the Developing World
The World Health Organization (WHO) issued a new set of guidelines suggesting all HIV-positive people in the world’s poorer countries start treatment when their CD4 counts fall below 350. These recommendations replace the previous ones, which advised positive people with no symptoms to start meds when CD4s hit 200.
WHO.int/hiv/pub/arv/advice/en/index.html

What’s Missing

The new guidelines skirt some key considerations about when to start treatment. Two of these urgent issues:

Many Americans don’t discover they are living with HIV until they get sick—often when their CD4 counts are well below 350. For them, the new numbers mean little. The biggest question remains how to encourage people to get tested and into care early, increasing their chances of survival and offering them a wider array of options for treatment.

Gregg Gonsalves, of the International Treatment Preparedness Coalition, says the new WHO recommendations could result in more people vying for the same pool of medication. There are not enough meds to go around already; treating all positive people with 350 CD4s could create further shortages for those who are critically ill. “Millions of people eligible for antiretroviral treatment under the old WHO guidelines—because they have clinical symptoms or CD4 counts below 200—still cannot get access to this lifesaving medication,” Gonsalves told POZ. “While the new WHO guidelines make sense clinically, those who are sickest should remain the first priority for AIDS treatment.”      

Search: U.S., CD4 counts, Europe, AIDS Clinical Society, EACS, hepatitis, guidelines, heart disease, WHO


Scroll down to comment on this story.



Name:

(will display; 2-50 characters)

Email:

(will NOT display)

City:

(will display; optional)

Comment (500 characters left):

(Note: The POZ team reviews all comments before they are posted. Please do not include either ":" or "@" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules



Show comments (0 total)

 
[Go to top]

Join POZ Facebook Twitter Google+ MySpace YouTube Tumblr Flickr
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar


    Hillcrester
    Ramona
    California


    zeze42
    Bay Area - Peninsula
    California


    Deelight4u
    BROOKLYN
    New York

This could be you!
Click here to join POZ Personals!
Ask POZ Pharmacist

Talk to Us
Poll
Survey
Pop Watch

more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2014 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.